■粒细胞集落刺激因子(G-CSF)和plerixafor的组合是多发性骨髓瘤(MM)患者造血干细胞动员的方法之一,非霍奇金淋巴瘤(NHL),和霍奇金淋巴瘤(HL)。本系统评价和荟萃分析旨在确定G-CSF+plerixafor动员外周血(PB)CD34+细胞的能力,并检查其安全性。
■我们使用术语“粒细胞集落刺激因子”进行了数据库搜索,\'G-CSF\',\'AMD3100\',和\'plerixafor\',直到2023年5月1日。该方法在PROSPERO数据库(CRD42023425760)中有更详细的描述。
■本系统综述和荟萃分析纳入了23项研究。与单独使用G-CSF相比,G-CSFplerixafor导致更多的患者获得了预定的CD34细胞单采率(OR,5.33;95%,4.34-6.55)。进一步发现G-CSF+plerixafor可以动员更多的CD34+细胞进入PB,这有利于下一次移植在两个随机对照(MD,18.30;95%,8.74-27.85)和单臂(MD,20.67;95%,14.34-27.00)试验。此外,与单独使用G-CSF相比,G-CSF+plerixafor并未引起更多的治疗紧急不良事件(OR,1.25;95%,0.87-1.80)。
■这项研究表明,G-CSF和plerixafor的组合,导致更多的MM患者,NHL,和HL,达到CD34+细胞的预定单采率,这与CD34+细胞更有效地动员到PB中有关。
UNASSIGNED: The combination of granulocyte-colony stimulating factor (G-CSF) and plerixafor is one of the approaches for hematopoietic stem cell mobilization in patients with multiple myeloma (MM), non-Hodgkin\'s lymphoma (NHL), and Hodgkin\'s lymphoma (HL). This systematic
review and meta-analysis aimed to determine the ability of G-CSF + plerixafor to mobilize peripheral blood (PB) CD34+ cells and examine its safety profile.
UNASSIGNED: We performed a database search using the terms \'granulocyte colony stimulating factor\', \'G-CSF\', \'AMD3100\', and \'plerixafor\', published up to May 1, 2023. The methodology is described in further detail in the PROSPERO database (CRD42023425760).
UNASSIGNED: Twenty-three studies were included in this systematic
review and meta-analysis. G-CSF + plerixafor resulted in more patients achieving the predetermined apheresis yield of CD34+ cells than G-CSF alone (OR, 5.33; 95%, 4.34-6.55). It was further discovered that G-CSF + plerixafor could mobilize more CD34+ cells into PB, which was beneficial for the next transplantation in both randomized controlled (MD, 18.30; 95%, 8.74-27.85) and single-arm (MD, 20.67; 95%, 14.34-27.00) trials. Furthermore, G-CSF + plerixafor did not cause more treatment emergent adverse events than G-CSF alone (OR, 1.25; 95%, 0.87-1.80).
UNASSIGNED: This study suggests that the combination of G-CSF and plerixafor, resulted in more patients with MM, NHL, and HL, achieving the predetermined apheresis yield of CD34+ cells, which is related to the more effective mobilization of CD34+ cells into PB.